TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30803542

Group type: EXPERIMENTAL
Intervention: 1.5% NaOCl irrigation (1.5 N)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl irrigation (2.5 N)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.5 N + intermittent canal brushing with Navitip FX (NFX)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.5 N + intermittent XP-endo Finisher (XPF)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.5 N + circumferential filing (CF)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.5 N + 1-min Self-adjusting File (SAF)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.5 N + mechanical instrumentation using #90–110 files (MI)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.5 N + intermittent passive ultrasonic irrigation (PUI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Initial (no intervention)
Number of subjects: 94
Study: 29158593

Group type: EXPERIMENTAL
Intervention: Surgical intervention for CLP (three different surgical strategies)
Number of subjects: 429
Study: 28323586

Group type: EXPERIMENTAL
Intervention: Home cervical traction
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no traction)
Number of subjects: 21
Study: 24338514

Group type: EXPERIMENTAL
Intervention: Pilocarpine eye test administered to children with BHS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group of healthy children
Number of subjects: 30
Study: 22008384

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 19615915

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% bolus (20 ml) before rib spreading (pre-RS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% bolus (20 ml) after rib spreading (post-RS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anterior thoracotomy (AT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Posterolateral thoracotomy (PT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre-RS (AT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-RS (AT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre-RS (PT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-RS (PT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Need for meperidine as a rescue drug
Number of subjects: 60
Study: 17518923

Group type: EXPERIMENTAL
Intervention: Neuromotor task training (NTT), 9 weekly sessions of 30 minutes each
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention for at least 9 weeks)
Number of subjects: 26
Study: 15370633

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (250 mL, 5 ppm F)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-fluoridated milk
Number of subjects: 20
Study: 11842840

Group type: EXPERIMENTAL
Intervention: Thick palatal appliance
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 18
Study: 9704737

Group type: COMPARATOR
Intervention: Intermediate-dose methotrexate (IDMTX) with leucovorin rescue (regimen A)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Regimen A plus asparaginase (ASP) (regimen B)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Regimen A plus a 24-hour infusion of cytarabine (AraC) (regimen C)
Number of subjects: 727
Study: 7983238

Group type: EXPERIMENTAL
Intervention: Sustained-release codeine (SRC) 150 mg every 12 hours for 5 doses
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immediate-release codeine phosphate (IRC) 60 mg (2 x 30 mg) every 4 hours for the first 3 doses, and 30 mg every 4 hours thereafter for 12 doses
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sustained-release codeine (SRC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immediate-release codeine phosphate (IRC)
Number of subjects: 13
Study: 2480613

Group type: EXPERIMENTAL
Intervention: Sulpiride (400, 800, or 1200 mg daily for 6 weeks)
Number of subjects: 24
Study: 30537561

Group type: EXPERIMENTAL
Intervention: 2,000 JAU
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: 5,000 JAU
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: 10,000 JAU
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1042
Study: 28699556

Group type: EXPERIMENTAL
Intervention: Community-designed interventions for dengue prevention, specific actions not detailed, duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-led trials with participatory research protocol, specific actions not detailed, duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community involvement in dengue control activities, specific actions not detailed, duration not available.
Number of subjects: 0
Study: 23828912

Group type: EXPERIMENTAL
Intervention: HPS school
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HE school
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control school
Number of subjects: 3
Study: 23562431

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 2528

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 2528

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 2528
Study: 21982141

Group type: EXPERIMENTAL
Intervention: Meditation training (28 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 19375570

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 82

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 82
Study: 17472818

Group type: EXPERIMENTAL
Intervention: Intensive-dose statin therapy (atorvastatin or simvastatin 80 mg)
Number of subjects: 27548
Study: 15107158

Group type: EXPERIMENTAL
Intervention: Smiling faces (positively perceived novel faces)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal association with positive affect (positively valenced prime)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants in happy mood states
Number of subjects: 0
Study: 11134500

Group type: EXPERIMENTAL
Intervention: Glycyl-L-tyrosine (graded levels)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study: 8956926

Group type: EXPERIMENTAL
Intervention: Biofeedback training with feedback trials and transfer trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 12
Study: 2123946

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Polymyxin B
Number of subjects: 24
Study: 6991102

Group type: EXPERIMENTAL
Intervention: Combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Methyl‐CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 157
Study: 31257430

Group type: EXPERIMENTAL
Intervention: Virgin coconut oil application (Group A)
Number of subjects: 2294

Group type: COMPARATOR
Intervention: Body massage without any application (Group B)
Number of subjects: 2294
Study: 30641346

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS (2400 pulses/session)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS (2400 pulses/session)
Number of subjects: 44
Study: 28616929

Group type: EXPERIMENTAL
Intervention: He‐Ne laser therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no He‐Ne laser therapy)
Number of subjects: 40
Study: 25592805

Group type: EXPERIMENTAL
Intervention: Quetiapine extended release (XR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Quetiapine immediate release (IR)
Number of subjects: 66
Study: 24685117

Group type: EXPERIMENTAL
Intervention: Electronic reminder activated in the patient's electronic medical record during a synchronous medical appointment throughout the year of intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no electronic reminder)
Number of subjects: 0
Study: 22011946

Group type: EXPERIMENTAL
Intervention: Medically supervised weight management (MSWM) program with monthly visits over 6 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care for 6 months
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Medically supervised weight management (MSWM) program
Number of subjects: 55
Study: 20701962

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Comparison between Vertebroplasty and Conservative treatment
Number of subjects: 202
Study: 18614861

Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg qd
Number of subjects: 689

Group type: COMPARATOR
Intervention: LPV/r 800/200 mg total daily dose
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: DRV/r in patients with HIV-1 RNA ≥ 100,000 copies/ml
Number of subjects: 689

Group type: COMPARATOR
Intervention: LPV/r in patients with HIV-1 RNA ≥ 100,000 copies/ml
Number of subjects: 689
Study: 15747448

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 micrograms/day
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 micrograms/day
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Alendronic acid
Number of subjects: 1637
Study: 11834100

Group type: EXPERIMENTAL
Intervention: Eccentric loading with detaching hooks (105% of concentric 1RM for lowering, 100% for raising)
Number of subjects: 8
Study: 10520081

Group type: EXPERIMENTAL
Intervention: Inhaled ET-1 (nebulized dose range 0.96-15.36 nmol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8774159

Group type: EXPERIMENTAL
Intervention: 25 mg of high molecular weight hyaluronan
Number of subjects: 240

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 240
Study: 1730816

Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg/day, intravaginally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: GnRH (10 microgram/pulse every 90 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6377712

Group type: EXPERIMENTAL
Intervention: co‐tetroxazine (100 mg tetroxoprim and 250 mg sulphadiazine) b.i.d.
Number of subjects: 127

Group type: COMPARATOR
Intervention: co‐trimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole) b.i.d.
Number of subjects: 127
Study: 30624198

Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Education plus pharmacist consultation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 150
Study: 29188338

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (PG 2.8 ± 0.2 mmol/l, approximate duration 55 min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Euglycaemia (PG 5.5 mmol/l ± 10%)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (PG 2.8 ± 0.2 mmol/l)
Number of subjects: 26
Study: 26325537

Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange (HVP) for three days
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange (HVP) prior to transplantation
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange (HVP)
Number of subjects: 182
Study: 25475465

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 207566
Study: 22840725

Group type: EXPERIMENTAL
Intervention: Delivery without stirrups
Number of subjects: 214

Group type: COMPARATOR
Intervention: Delivery in stirrups
Number of subjects: 214
Study: 19644125

Group type: EXPERIMENTAL
Intervention: Treatment for simple target phonemes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Treatment for complex targets
Number of subjects: 6
Study: 16329785

Group type: EXPERIMENTAL
Intervention: 2-day burnout intervention program
Number of subjects: 59
Study: 12150629

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adenoidectomy (T&A)
Number of subjects: 41
Study: 9785144

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg per day (initially 2.5 to 5 mg, increased to 10 mg in five patients)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 9
Study: 7884424

Group type: EXPERIMENTAL
Intervention: Intrapleural cisplatin (IPL CDDP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (IP CDDP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intracavitary cisplatin (IC CDDP)
Number of subjects: 11
Study: 2346543

Group type: EXPERIMENTAL
Intervention: 3000 mg acetylsalicylic acid (ASA) daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3000 mg paracetamol daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 380725

Group type: EXPERIMENTAL
Intervention: Bromocryptine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 30282645

Group type: EXPERIMENTAL
Intervention: NHS Health Check attendance
Number of subjects: 138788

Group type: EXPERIMENTAL
Intervention: NHS Health Check attendees
Number of subjects: 138788

Group type: EXPERIMENTAL
Intervention: NHS Health Check attendees in deprived areas
Number of subjects: 138788

Group type: COMPARATOR
Intervention: Non-attendees
Number of subjects: 138788
Study: 28121498

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 2655

Group type: EXPERIMENTAL
Intervention: Actoxumab plus bezlotoxumab (10 mg/kg each)
Number of subjects: 2655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2655
Study: 25746086

Group type: EXPERIMENTAL
Intervention: Self-needling
Number of subjects: 67
Study: 23506972

Group type: EXPERIMENTAL
Intervention: Intracoronary darbepoetin‐α (ARANESP®; Jeil‐Kirin Pharm., Korea) 300μg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 80
Study: 21775528

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index diet (LGI; GI: 79)
Number of subjects: 29

Group type: COMPARATOR
Intervention: High Glycemic Index diet (HGI; GI: 103)
Number of subjects: 29
Study: 20054092

Group type: EXPERIMENTAL
Intervention: Mailing of the trial information sheet separate from the screening invitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extension of recruitment to mobile screening units in Nottingham
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of an additional member of staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simplification of the trial information sheet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall acceptance rate of trial participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall recruitment rate over time
Number of subjects: 0
Study: 17122577

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 15
Study: 14710137

Group type: EXPERIMENTAL
Intervention: Support by untrained lay women starting in early labor and continuing into the postpartum period
Number of subjects: 8

Group type: COMPARATOR
Intervention: Trained lay women, female relatives, nurses, lay midwives, and student lay midwives
Number of subjects: 8
Study: 11723269

Group type: EXPERIMENTAL
Intervention: Almotriptan 2 mg
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study: 9038425

Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Baseline total BOD value
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Percent changes in BOD from baseline to exit
Number of subjects: 163
Study: 8188893

Group type: COMPARATOR
Intervention: Liquid nitrogen cryotherapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Argon laser therapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CO2 laser therapy
Number of subjects: 13
Study: 2959882

Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29685777

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% drops
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 27450973

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) in normokalemia patients
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fever control in normokalemia patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) in hypokalemia patients
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fever control in hypokalemia patients
Number of subjects: 135
Study: 25124186

Group type: EXPERIMENTAL
Intervention: Stenting (PCI)
Number of subjects: 4566

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4566
Study: 22755547

Group type: EXPERIMENTAL
Intervention: Patient/therapist feedback and clinical decision-support tools
Number of subjects: 370

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 370
Study: 20629698

Group type: EXPERIMENTAL
Intervention: Cannula valve connector
Number of subjects: 290

Group type: COMPARATOR
Intervention: No cannula valve connector
Number of subjects: 290
Study: 18714934

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft
Number of subjects: 7

Group type: COMPARATOR
Intervention: Connective tissue graft with coronally positioned flap
Number of subjects: 7
Study: 15823228

Group type: EXPERIMENTAL
Intervention: quarter-laser zona thinning assisted hatching (qLZT-AH)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no qLZT-AH)
Number of subjects: 150
Study: 12208708

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Artisan phakic intraocular lens (PIOL)
Number of subjects: 25
Study: 10604044

Group type: EXPERIMENTAL
Intervention: Azelastine combination therapy (azelastine nasal spray 0.14 mg twice daily + azelastine tablet 2 mg at night)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Azelastine nasal spray only (after day five)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo tablet with nasal spray (control group)
Number of subjects: 300
Study: 7723663

Group type: EXPERIMENTAL
Intervention: Testosterone treatment for 2 years (Group 1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Testosterone treatment for 1 year followed by 1 year without treatment (Group 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (both groups)
Number of subjects: 12
Study: 1975162

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 micrograms twice a day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled salbutamol 200 micrograms four times a day
Number of subjects: 12
Study: 18492

Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam
Number of subjects: 118

Group type: COMPARATOR
Intervention: 30 mg flurazepam
Number of subjects: 118
Study: 31562569

Group type: EXPERIMENTAL
Intervention: Peer education for 1 year
Number of subjects: 1564
Study: 31088887

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 26
Study: 28489877

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention, including at least 1 hour/day of moderate PA and additional strenuous weekly activity, collective walks, and theoretical group sessions.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no PA intervention).
Number of subjects: 210

Group type: COMPARATOR
Intervention: Overall comparison of PA intervention vs control.
Number of subjects: 210
Study: 25616944

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided inguinal field block (n = 42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Spinal anesthesia block (n = 44)
Number of subjects: 86
Study: 23347259

Group type: EXPERIMENTAL
Intervention: Hand-carried ultrasound (HCU) examination by briefly trained medical students
Number of subjects: 45

Group type: COMPARATOR
Intervention: Auscultation-based physical examination
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard echocardiography study
Number of subjects: 45
Study: 21622774

Group type: EXPERIMENTAL
Intervention: Pegloticase
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 18799509

Group type: EXPERIMENTAL
Intervention: Sniff nasal inspiratory pressure
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Neuromuscular disease (NM)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Thoracic scoliosis
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Normal value of sniff nasal pressure
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Low value of sniff nasal pressure
Number of subjects: 113
Study: 16923414

Group type: EXPERIMENTAL
Intervention: TandemHeart percutaneous ventricular assist device (pVAD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intraaortic balloon pumping (IABP)
Number of subjects: 42
Study: 15191618

Group type: EXPERIMENTAL
Intervention: N‐Acetyl Aspartate (NAA/Cr ratio) levels in normal appearing white matter
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Functional Composite score
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Neurological Rating Scale
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ambulation Index scale
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Expanded Disability Scale Score
Number of subjects: 31
Study: 11300387

Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block with bupivacaine 1 mg x kg(‐1) 7.5 mg x ml(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block with ropivacaine 1 mg x kg(‐1) 7.5 mg x ml(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Spinal anaesthesia only
Number of subjects: 75
Study: 9597417

Group type: EXPERIMENTAL
Intervention: Levosimendan 8 micrograms.kg-1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Levosimendan 24 micrograms.kg-1
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23